Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...
Pen Needles Market Insight BURLINGAME, CA, UNITED STATES, February 5, 2025 /EINPresswire / -- The Pen Needles Market Report is the result of e ...
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
The Girl with the Needle is a historical ... is produced by Malene Blenkov and Mariusz Włodarski under the banner of Nordisk Film Denmark, Lava Films, Lower Silesia Film Centre, EC1 Łódź ...
We may earn a commission if you make a purchase from the links on this page. The high-end Galaxy S25 Ultra's S Pen doesn't support Bluetooth, so it loses some cool features like remote control for ...
A new study found that patients taking GLP-1s to treat type 2 diabetes have a lower risk of developing Alzheimer’s disease, potentially opening the door … ...
Novo Nordisk has announced topline results from the phase 3b trial STEP UP, which investigated the effects of two doses of Wegovy (semaglutide) in over 1,400 patients over the course of 72 weeks. Both ...
Shortly after sunrise, John Gobbi stepped gingerly across a sidewalk in Boston’s South End strewn with dirty and discarded drug needles. Every so often his work boots crushed another syringe ...
Bernard Arnault is once again in charge of Europe's most valuable company. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...
Novo Nordisk has commenced the STEP UP and STEP UP T2D trials to explore the efficacy of semaglutide 7.2mg. Credit: © 2025 Novo Nordisk A/S. Novo Nordisk’s high ...
Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results